Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents.

[1]  T. Stijnen,et al.  Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis. , 2010, European heart journal.

[2]  R. Virmani,et al.  Comparison of Inflammatory Response After Implantation of Sirolimus- and Paclitaxel-Eluting Stents in Porcine Coronary Arteries , 2009, Circulation.

[3]  R. Virmani,et al.  Drug-eluting stent safety: findings from preclinical studies , 2008, Expert review of cardiovascular therapy.

[4]  Aloke V. Finn,et al.  Delayed Arterial Healing and Increased Late Stent Thrombosis at Culprit Sites After Drug-Eluting Stent Placement for Acute Myocardial Infarction Patients: An Autopsy Study , 2008, Circulation.

[5]  M. Takano,et al.  Lack of Association Between Large Angiographic Late Loss and Low Risk of In-Stent ThrombusCLINICAL PERSPECTIVE , 2008 .

[6]  M. Takano,et al.  Lack of Association Between Large Angiographic Late Loss and Low Risk of In-Stent Thrombus: Angioscopic Comparison Between Paclitaxel- and Sirolimus-Eluting Stents , 2008, Circulation. Cardiovascular interventions.

[7]  B. Gersh.  A Comparison of Bare-Metal and Drug-Eluting Stents for Off-Label Indications , 2008 .

[8]  Patrick W Serruys,et al.  Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. , 2007, Journal of the American College of Cardiology.

[9]  R. Virmani,et al.  Pathological Correlates of Late Drug-Eluting Stent Thrombosis: Strut Coverage as a Marker of Endothelialization , 2007, Circulation.

[10]  Rolf Vogel,et al.  Incomplete Stent Apposition and Very Late Stent Thrombosis After Drug-Eluting Stent Implantation , 2007, Circulation.

[11]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[12]  Timothy J Gardner,et al.  Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American D , 2007, Circulation.

[13]  Ralph D'Agostino,et al.  Stent thrombosis in randomized clinical trials of drug-eluting stents. , 2007, The New England journal of medicine.

[14]  S. Pocock,et al.  Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. , 2007, The New England journal of medicine.

[15]  Neville Kukreja,et al.  Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study , 2007, The Lancet.

[16]  Michael Joner,et al.  Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. , 2006, Journal of the American College of Cardiology.

[17]  P. Serruys,et al.  Peristent Remodeling and Neointimal Suppression 2 Years After Polymer-Based, Paclitaxel-Eluting Stent Implantation: Insights From Serial Intravascular Ultrasound Analysis in the TAXUS II Study , 2005, Circulation.

[18]  Patrick W Serruys,et al.  Evaluation of four-year coronary artery response after sirolimus-eluting stent implantation using serial quantitative intravascular ultrasound and computer-assisted grayscale value analysis for plaque composition in event-free patients. , 2005, Journal of the American College of Cardiology.

[19]  P. Fitzgerald,et al.  Late incomplete stent apposition after sirolimus-eluting stent implantation: a serial intravascular ultrasound analysis. , 2005, Journal of the American College of Cardiology.

[20]  F. Eberli,et al.  Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. , 2005, The New England journal of medicine.

[21]  R. Virmani,et al.  Differential Response of Delayed Healing and Persistent Inflammation at Sites of Overlapping Sirolimus- or Paclitaxel-Eluting Stents , 2005, Circulation.

[22]  Patrick W Serruys,et al.  Four-Year Angiographic and Intravascular Ultrasound Follow-Up of Patients Treated With Sirolimus-Eluting Stents , 2005, Circulation.

[23]  P. Serruys,et al.  Incomplete Stent Apposition After Implantation of Paclitaxel-Eluting Stents or Bare Metal Stents: Insights From the Randomized TAXUS II Trial , 2005, Circulation.

[24]  R. Virmani,et al.  Extracellular Matrix Changes in Stented Human Coronary Arteries , 2004, Circulation.

[25]  Giuseppe Musumeci,et al.  Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting Stent: Should We Be Cautious? , 2004, Circulation.

[26]  G. Stone,et al.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. , 2004, The New England journal of medicine.

[27]  Jeffrey W Moses,et al.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.

[28]  Renu Virmani,et al.  Morphological Predictors of Restenosis After Coronary Stenting in Humans , 2002, Circulation.

[29]  R. Virmani,et al.  Pathological Analysis of Local Delivery of Paclitaxel Via a Polymer-Coated Stent , 2001, Circulation.

[30]  B. Abella,et al.  Paclitaxel Stent Coating Inhibits Neointimal Hyperplasia at 4 Weeks in a Porcine Model of Coronary Restenosis , 2001, Circulation.

[31]  W. Thompson,et al.  Smooth muscle cell outgrowth stimulated by fibrin degradation products. The potential role of fibrin fragment E in restenosis and atherogenesis. , 2000, Thrombosis research.

[32]  H Yokoi,et al.  Three-year follow-up after implantation of metallic coronary-artery stents. , 1996, The New England journal of medicine.

[33]  K. Tanaka,et al.  Effects of fibrin and fibrinogen-degradation products on the growth of rabbit aortic smooth muscle cells in culture. , 1982, Atherosclerosis.

[34]  Lee G Luna,et al.  Manual of histologic staining methods of the Armed forces institute of pathology , 1968 .